Lynk Pharmaceuticals
- Biotech or pharma, therapeutic R&D
Lynk is a clinical-stage company focusing on autoimmune indications. Differentiated assets:
LNK01001: Best-in-Class JAK1i (Ph3) for I&I,
LNK01004: Tissue-restricted JAKi for Derm (Ph2)
LNK01006: CNS penetrant TYK2i (IND) for MS, PD, AMD and others
LNK-10002244: Systemic TYK2i for Type 1 diabetes & IBD (IND enabling)
LNK-10002282: Topical TYK2i for skin indications (PCC)
LNK-009: Oral IL-23i for Psoriasis and IBD (PCC)
LNK-011: Novel oral VAV1 degraders for various autoimmune indications (PCC candidates)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}